Restoration of the antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells. 2008

Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL 60612, USA.

Emergence of antiviral drug resistance is a major challenge to human immunodeficiency virus (HIV) therapy. The archetypal example of this problem is loss of antiviral activity of the nucleoside analogue 3'-azido-3'-deoxythymidine (AZT), caused by mutations in reverse transcriptase (RT), the viral polymerase. AZT resistance results from an imbalance between rates of AZT-induced proviral DNA chain termination and RT-induced excision of the chain-terminating nucleotide. Conversion of the AZT prodrug from its monophosphorylated to diphosphorylated form by human thymidylate kinase (TMPK) is inefficient, resulting in accumulation of the monophosphorylated AZT metabolite (AZT-MP) and a low concentration of the active triphosphorylated metabolite (AZT-TP). We reasoned that introduction of an engineered, highly active TMPK into T cells would overcome this functional bottleneck in AZT activation and thereby shift the balance of AZT activity sufficiently to block replication of formerly AZT-resistant HIV. Molecular engineering was used to link highly active, engineered TMPKs to the protein transduction domain of Tat for direct cell delivery. Combined treatment of HIV-infected T cells with AZT and these cell-permeable, engineered TMPKs restored AZT-induced repression of viral production. These results provide an experimental basis for the development of new strategies to therapeutically increase the intracellular concentrations of active nucleoside analogue metabolites as a means to overcome emerging drug resistance.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009703 Nucleoside-Phosphate Kinase An enzyme that catalyzes reversible reactions of a nucleoside triphosphate, e.g., ATP, with a nucleoside monophosphate, e.g., UMP, to form ADP and UDP. Many nucleoside monophosphates can act as acceptor while many ribo- and deoxyribonucleoside triphosphates can act as donor. EC 2.7.4.4. Nucleoside Monophosphate Kinases,Kinase, Nucleoside-Phosphate,Kinases, Nucleoside Monophosphate,Monophosphate Kinases, Nucleoside,Nucleoside Phosphate Kinase
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D016655 HIV Core Protein p24 A major core protein of the human immunodeficiency virus encoded by the HIV gag gene. HIV-seropositive individuals mount a significant immune response to p24 and thus detection of antibodies to p24 is one basis for determining HIV infection by ELISA and Western blot assays. The protein is also being investigated as a potential HIV immunogen in vaccines. HIV Major Core Protein p24,HIV gag Gene Product p24,HIV p24 Antigen,gag Protein p24, HIV,p24(HIV),HIV Protein p24,HTLV-III p24,p24 protein, Human Immunodeficiency Virus,HTLV III p24,p24 Antigen, HIV,p24, HIV Protein,p24, HTLV-III

Related Publications

Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
February 1999, Antimicrobial agents and chemotherapy,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
June 1998, Journal of virology,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
January 1991, Journal of virology,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
October 2000, Journal of virology,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
March 2005, The Journal of general virology,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
May 1992, Antiviral research,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
August 1989, Journal of medicinal chemistry,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
April 1988, Acta crystallographica. Section C, Crystal structure communications,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
June 1990, Antimicrobial agents and chemotherapy,
Arnon Lavie, and Ying Su, and Mahmood Ghassemi, and Richard M Novak, and Michael Caffrey, and Nikolina Sekulic, and Christian Monnerjahn, and Manfred Konrad, and James L Cook
January 1987, Lancet (London, England),
Copied contents to your clipboard!